Rinisona

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rinisona

Rinisona is a medicine whose identity is defined by its active ingredient, Fluticasone Propionate, a powerful compound designed to manage localized inflammatory conditions in the nose.

Property Description
Active ingredient Fluticasone Propionate (INN)
Form Aqueous nasal spray suspension (metered-dose)
Pharmacological class Glucocorticoid / Corticosteroid (Nasal)
Common use Relief of symptoms associated with nasal inflammation
Origin Synthetic fluorinated steroid derivative

What Type of Medicine is Rinisona?

Rinisona is a medicinal product containing the single active ingredient Fluticasone Propionate, which classifies it as a synthetic glucocorticoid—a type of corticosteroid. It is supplied as an aqueous nasal spray suspension, a formulation specifically developed for direct, topical intranasal administration to the nasal lining.

This glucocorticoid class is recognized by medical professionals for its potent anti-inflammatory effects. The formulation is structured to ensure that the medicine is concentrated at the required site of action while limiting systemic absorption.

Composition: Is Fluticasone Propionate a Steroid?

Yes, Fluticasone Propionate is structurally a synthetic fluorinated steroid derivative, created for its high potency and long duration of action as an anti-inflammatory compound. Rinisona contains the active ingredient suspended within an aqueous vehicle (a water-based liquid carrier system) for precise and gentle delivery to the nasal mucosa.

Fluticasone Propionate exhibits a strong affinity for the glucocorticoid receptor, a chemical property that underpins its effectiveness. Unlike some older steroid products, modern aqueous nasal sprays, like Rinisona, typically lack propellants, making them comfortable for regular patient use.

General Purpose: How Does Rinisona Provide Relief?

The primary general purpose of Rinisona is to exert a powerful local anti-inflammatory and immunosuppressive effect directly on the nasal passages. This action works by blocking the release of multiple inflammatory substances, including histamine, prostaglandins, and cytokines.

By strongly controlling the underlying biological inflammation, the medicine helps minimize swelling and reduce the symptoms driven by tissue hyperactivity. Rinisona is typically utilized in situations requiring sustained control over inflammatory symptoms. The targeted, multi-pathway action provides relief by assisting in the restoration of a more normal physiological state within the nasal passages.

What side effects are possible with Rinisona?

Possible Side Effects and Safety Information

The official safety profile for Rinisona (Fluticasone Propionate nasal spray) is structured by regulatory authorities around documented adverse reactions and specific safety constraints. The most frequently observed events are generally localized to the nasal passages.


Documented Adverse Reactions by Frequency

Adverse reactions are classified according to standard regulatory terminology, with the majority being local effects:

  • Very Common (ge 1/10): Epistaxis (nosebleeds).
  • Common (ge 1/100 to < 1/10): Headache, nasal dryness, nasal irritation, and throat irritation.
  • Very Rare (< 1/10,000): Severe Hypersensitivity reactions (including anaphylaxis, angioedema), Nasal Septal Perforation, Glaucoma, and Cataract.

These effects are generally grouped into System-Organ Classes, primarily focusing on Respiratory, Thoracic, and Mediastinal Disorders.


Serious Safety Considerations

The regulatory safety profile notes the potential for serious adverse reactions such as Nasal Septal Perforation and the development of Glaucoma or Cataract. These ocular issues are particularly associated with the long-term use of intranasal corticosteroids.

Specific safety considerations apply to certain groups. Growth retardation is a documented risk for the pediatric population on long-term therapy. The label also contains constraints regarding use in patients with unhealed nasal wounds or recent nasal surgery, and notes that co-administration with strong CYP3A4 inhibitors may increase the potential for systemic corticosteroid effects.

This framework clarifies that while local effects are common, the primary safety concerns regarding systemic effects are linked to duration of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based solely on the official overdose profile for Rinisona (Fluticasone Propionate) as documented in government regulatory sources.

The regulatory profile for Rinisona distinguishes between the low acute toxicity risk and the potential for effects following chronic, supra-therapeutic exposure. Acute overdose, such as short-term inhalation or ingestion of high doses, is generally considered unlikely to cause acute clinical problems due to the nasal spray’s low systemic absorption.

The main documented concern from prolonged use of excessive doses is the potential development of clinical signs of hypercorticism and the serious physiological finding of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Emergency Response and Management Official Regulatory Statement
When to Seek Help Seek immediate medical attention for a suspected overdose.
Antidote Availability No specific antidote is known for this medicine.
Management Protocol Treatment is restricted to symptomatic and supportive treatment.

If chronic overdose leads to HPA axis suppression, the mandated procedural action is the gradual withdrawal of the medicine. Acute overdose monitoring is typically not required. For any suspected overdose event, regardless of acute symptom presentation, the official instruction remains to seek immediate medical attention.

Therapeutic Uses of Rinisona

Rinisona (which contains fluticasone propionate) is a prescription or over-the-counter nasal spray that provides symptom relief for a range of nasal and sinus conditions. It is indicated for the management of nasal issues associated with seasonal or perennial allergic rhinitis, such as hay fever.

Quick Facts

  • Addresses sneezing and a runny, stuffy, or itchy nose.
  • Aids in the relief of discomfort caused by seasonal and year-round allergies.
  • Supports the treatment of chronic rhinosinusitis with or without nasal polyps (in specific formulations and age groups).

This medication is approved for use to help alleviate symptoms of nonallergic rhinitis and is used to support therapy for chronic rhinosinusitis with or without nasal polyps in adults, depending on the specific formulation. It contributes to reducing congestion, assisting patients in achieving a better level of comfort when used consistently as directed.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rinisona — Official Regulatory Information


Eligibility Scope

Category Eligibility Rule (Strictly Regulatory Statement)
Populations for whom use is allowed (as stated in label) Adults, adolescents, and pediatric patients 4 years of age and older.
Populations for whom use is not recommended (if applicable) Children younger than 4 years of age, as safety and effectiveness have not been established.
Populations for whom use is contraindicated Patients with known hypersensitivity or allergic reactions to Fluticasone Propionate or any formulation component.
Age-related eligibility rules Use is established in adults and children ge 4 years. Use is generally permitted for older adults without specific dose adjustments.
Condition-specific eligibility rules Caution is advised in patients with moderate to severe hepatic impairment due to potential for increased systemic exposure. No dosage adjustment is required for renal impairment.
Pregnancy and lactation eligibility status (if explicitly documented) Use is permitted only if the potential benefit justifies the potential risk to the fetus or infant.
Eligibility-related restrictions Use must be avoided with recent nasal ulcers, nasal trauma, or surgery until healing is complete. Caution is required with active tuberculosis or other systemic infections.

Eligibility Classifications (High-Level)

Category Regulatory Status (as defined in official documents)
Eligibility severity classification (as defined in official documents) Contraindicated (Hypersensitivity) and Conditional/Caution (Severe Hepatic Impairment, Specific Infections, Pregnancy/Lactation).
Regulatory basis (EMA / FDA / etc.) Based on FDA Prescribing Information and EMA/UK Summary of Product Characteristics (SmPC).
Eligibility-context constraints (as defined in official documents) Use requires monitoring in patients with a history of glaucoma or cataracts.

Resulting Eligibility Structure

Official eligibility statements:

  • Rinisona is contraindicated in any patient with a documented history of hypersensitivity to its ingredients.
  • The medicine is established for use in adults and children mathbf4 years of age and older.
  • Caution is advised in the presence of moderate to severe hepatic impairment or active systemic infections like tuberculosis.

Connection to the overall eligibility profile (2–4 sentences):

The official regulatory documents define eligibility by establishing an absolute contraindication for hypersensitivity or unhealed nasal wounds, and by setting a minimum age-group eligibility of 4 years. Conditional limitations require caution or special monitoring for specific populations, including those with severe hepatic impairment or those who are pregnant or breastfeeding, where use is permitted only when the benefit is explicitly documented to outweigh the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Rinisona (Fluticasone Propionate) is defined primarily by its metabolism. The active substance is extensively cleared by the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Metabolic-Inhibitor Interactions

Co-administration with strong CYP3A4 inhibitors results in a pharmacokinetic interaction that causes a reduced clearance of Fluticasone Propionate. This interaction is officially documented to lead to increased systemic exposure and raises the risk of developing systemic corticosteroid effects.

Official Restrictions and Prohibitions

  • Ritonavir and Cobicistat: Combination with the potent inhibitors Ritonavir and products containing Cobicistat is explicitly not recommended or not advised in regulatory labeling due to the risk of severely increased systemic concentrations.
  • Other Potent Inhibitors: Other medicines noted to cause this effect include Ketoconazole, Itraconazole, and Clarithromycin.
  • Food Interactions: The consumption of Grapefruit Juice is also documented to cause this interaction, functioning as a strong CYP3A4 inhibitor that can increase systemic concentrations.
  • Population-Specific Note: Caution is noted for patients with severe hepatic impairment, as reduced clearance in this population may also lead to increased systemic effects. No mandatory timing-based rules for separating doses are specified.

Mechanism of Action

Targeted Genomic Reprogramming

The active component functions as an agonist for the intracellular Glucocorticoid Receptor ( GR), which is found in target cells within the nasal lining. Upon binding, the activated drug- GR complex translocates to the cell nucleus to initiate a genomic action. This mechanism involves both transrepression (inhibiting pro-inflammatory transcription factors like NF-kappa B) and transactivation (increasing the synthesis of anti-inflammatory proteins).

️ Inflammatory Cascade Suppression and Physiological Result

This genomic modulation achieves a broad-spectrum suppression across multiple inflammatory pathways. By functionally inhibiting enzymes such as Phospholipase A2 ( PLA2) and downregulating genetic output, the drug lowers the synthesis and subsequent release of major inflammatory mediators, including cytokines, prostaglandins, and histamine. Because this core effect relies on the synthesis of new proteins, the mechanism is characterized by a delayed onset of maximal physiological effect. The resulting consequence is decreased vascular permeability and reduced cellular infiltration (e.g., eosinophils) within the targeted tissue.

Dosage and Administration Information

How to Use Rinisona: Administration Guidelines

Rinisona (Fluticasone Propionate Nasal Spray) is formulated exclusively for topical intranasal administration directly to the lining of the nose. The correct usage protocol centers on consistent application and specific dosing ranges.

Dosing and Frequency

The standard adult dosing schedule begins with a starting total daily dose of 200 micrograms (μg), typically administered as two sprays (mathbf100 mu g) into each nostril once daily. Once symptom control is achieved, the dose is commonly reduced to a maintenance level of 100 μg total daily (one spray in each nostril once daily). The maximum total daily dose for adults must not exceed 200 μg. The primary schedule for both initial and maintenance therapy is once daily (QD).

Administration Requirements

The nasal spray device must be shaken well and primed (actuated several times into the air) before its first use or if it has not been used for a specific period (e.g., seven days). This preparation step is crucial to ensure that each metered spray delivers the labeled mathbf50 mu g dose. The medicine is intended for regular, scheduled use, as maximum effect is dependent on continuous application rather than as-needed use.

Population-Specific Use

For children 4 years and older, the usual dose is a maximum of 100 μg total daily (one spray in each nostril once daily). If a dose is missed, instructions advise against taking a double dose to compensate; the user should simply resume the regular schedule the following day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rinisona

This overview summarizes the structure of clinical research conducted for Rinisona (Fluticasone Propionate nasal spray), detailing what was measured in the studies and where gaps in the research still exist. This is a neutral summary of the evidence landscape.


Evidence for Use in Allergic Rhinitis (Hay Fever)

Research for both seasonal and perennial allergies primarily involved numerous Randomized Controlled Trials (RCTs). Studies consistently monitored patient-reported outcomes for core nasal symptoms, ocular symptoms, and outcomes reflecting daily functioning (QoL). Findings describe patterns observed across short-term (2–4 week) and longer periods. Despite the large volume of research, long-term effects are not fully established, and some analyses described statistical inconsistency in pooled measurements.


Evidence for Use in Nonallergic Rhinitis

Research that was studied for nasal symptoms not caused by allergies involved RCTs and integrated analyses. Studies examined changes in symptom intensity using total nasal symptom scores. However, the evidence quality varies across studies, and the body of work is assigned an evidence level of Moderate, suggesting that certainty remains low in some areas. Some initial trials findings were mixed, reflecting challenges due to the inconsistent definition of nonallergic rhinitis sub-types.


Evidence for Use in Chronic Rhinosinusitis with Nasal Polyps

The research was studied for conditions characterized by fluctuating manifestations like chronic rhinosinusitis with polyps, including controlled clinical trials. Studies monitored both objective outcomes (polyp size, anatomical scores) and patient-reported outcomes (SNOT-22). Findings were often generated using specialized drug delivery systems that differ from the standard nasal spray formulation. Therefore, the results apply only to the populations studied and the specific delivery methods used.


Long-Term Studies and Follow-up Duration

Clinical research has explored the outcomes over both short-term (2–4 week) periods and long-term (up to 1 year) intervals. This research focuses on observing responses over defined time intervals. While data show patterns related to use for up to a year, the long-term effects are not fully established for periods extending beyond this duration.


Research in Specific Patient Groups (Special Populations)

Research was conducted during periods of increased symptom activity and studies monitored different patient populations, including children (aged 4 years and older), adolescents, and adults. Evidence contributes to understanding symptom patterns in these younger populations, but data for certain groups remain insufficient regarding long-term continuous use.


What Research Gaps and Uncertainty Remain

The evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking in some areas, and research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Rinisona (FAQ)


Q: Are there any foods or drinks I should avoid while taking Rinisona?

A: Official regulatory documents specifically advise against consuming grapefruit juice. This is because official documents advise against consuming grapefruit juice, as it may cause an interaction by affecting how the medicine is processed in the body. No other specific foods or drinks are noted for avoidance in the official product information.


Q: Can Rinisona affect my ability to drive?

A: The official safety profile includes some documented side effects such as headache and, in very rare instances, dizziness or sleepiness. Official safety information indicates that these events could potentially impact concentration. The safety profile notes the importance of being aware of one's reaction to the medicine when performing tasks that require full mental alertness.


Q: What happens if I forget to take a dose of Rinisona?

A: Regulatory instructions on missed doses advise against taking a double dose to compensate. Regulatory instructions state that if a dose is missed, individuals should resume their regular schedule at the next scheduled time. The medicine is designed for continuous, regular use.


Q: Why is Rinisona sometimes used for different conditions than its primary one?

A: The active ingredient is classified as a glucocorticoid, a compound known for its local anti-inflammatory effect. This action helps to manage the common symptom of inflammation that characterizes a range of nasal conditions, such as allergic and non-allergic rhinitis.


Q: Does Rinisona require any specific blood tests while taking it?

A: Official product labeling does not typically mandate routine blood tests for all users. However, the official safety information indicates that patients with certain pre-existing conditions or those on long-term therapy may need monitoring for potential effects such as Glaucoma or Cataracts.


Q: Does taking Rinisona affect fertility?

A: Studies conducted in animals at certain doses did not show an effect on fertility. However, regulatory documents often indicate that comprehensive human data are insufficient to fully characterize all potential risks. Use during pregnancy and lactation is conditional.


Q: How quickly does Rinisona usually start working?

A: A decrease in symptoms may begin within 12 hours of the first dose. Its maximum benefit is typically achieved after several days of continuous, regular use, as described in official product information.


Q: How long does the effect of one dose of Rinisona last?

A: Regulatory guidelines describe the medication's schedule as once-daily (QD) use. This daily dosing schedule indicates that the pharmacological effects are generally considered to cover a 24-hour period when the medicine is used on a regular, scheduled basis according to official instructions.


Q: Is it normal to feel a mild side effect like [Non-Specific Side Effect] when starting Rinisona?

A: The official safety profile provides classification for how often different side effects were seen in trials. For example, epistaxis (nosebleeds) is classified as Very Common, and headache or nasal irritation as Common. These classifications describe the frequency with which these events were observed in clinical trials, particularly in the starting phase of treatment.


Q: Can older people use Rinisona?

A: Regulatory documents state that use is generally permitted for older adults (the geriatric population). The official information indicates that typically no specific dose adjustments are required for this population group, based on the established safety and effectiveness profile.


Q: What does official research say about the long-term use of Rinisona?

A: Research has explored outcomes over periods of up to one year. Official documents indicate that the long-term effects are not fully established for periods extending beyond that duration, reflecting a lack of comprehensive data for continuous use exceeding one year.


Q: Is Rinisona addictive or habit-forming?

A: The active ingredient in Rinisona is a glucocorticoid (corticosteroid). Regulatory documents do not contain any warnings or statements regarding the medicine being addictive or habit-forming.


Q: Does Rinisona cause weight gain or loss?

A: Weight change is generally not listed as a common adverse reaction in the official safety information. However, some regulatory summaries have noted weight gain as a less common event, sometimes associated with systemic effects that could occur from very high-dose or prolonged use.


Q: Is Rinisona a drug that needs to be tapered off?

A: For typical use, a specific tapering schedule is not required by regulatory documents. Tapering is only addressed in official documentation for individuals where there is evidence of systemic corticosteroid effects (such as adrenal suppression), which is a rare, conditional side effect.


Q: Is Rinisona a drug that needs to be taken every day?

A: The official product information describes the medicine as intended for regular, scheduled use rather than as-needed application. Its maximum benefit is dependent on continuous application.


Q: Is the efficacy of Rinisona affected by the time of day it is taken?

A: Regulatory documents note that the total daily dose can be taken once daily or divided into two smaller doses (e.g., morning and evening). Both methods of administration are described in official documents as effective schedules for this medicine.


Q: Is it possible for Rinisona to cause an allergic reaction?

A: Yes, severe hypersensitivity reactions (allergic reactions), including serious events like anaphylaxis and angioedema, are listed as a Very Rare adverse reaction in the official safety profile. The medicine is formally contraindicated for anyone with a known hypersensitivity to its ingredients.


Q: Do studies suggest that Rinisona is effective for long-term management?

A: Clinical research has explored outcomes over periods of up to one year, with findings showing patterns observed in symptom control. However, official documents indicate that data for long-term continuous use beyond one year remain insufficient to characterize its long-term management effectiveness in all patient groups.


Q: What is the typical age range for people prescribed Rinisona?

A: Official eligibility is established for use in adults, adolescents, and pediatric patients 4 years of age and older. The medicine is not recommended for children younger than 4 years of age, as safety and effectiveness have not been established in that population.


Q: Can Rinisona interact with supplements like St. John's Wort?

A: Official warnings about drug interactions primarily concern medicines that are strong CYP3A4 inhibitors. Because certain herbal supplements, such as St. John's Wort, are known to affect the CYP3A4 enzyme, official warnings about drug interactions apply to these substances due to the potential for increased systemic exposure.

How should Rinisona be stored and disposed of?

How to Store and Dispose of Rinisona?

Rinisona (Fluticasone Propionate Nasal Spray) requires specific storage and disposal procedures as documented in its official labeling to maintain product stability and safety.

Official Storage Requirements

Temperature and Protection: Store the medicine at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and must not be frozen.

Container and Safety: Keep the nasal spray out of the sight and reach of children and store the bottle upright in its original container with the cap secured. The unit must be discarded after the labeled spray count is reached or after a specific period (e.g., 2 months) following its first use.

Official Disposal Instructions

Unused or expired Rinisona should be disposed of using a local drug take-back program. If this is unavailable, the medicine must be mixed with an undesirable substance, sealed in a bag, and placed in household trash. It is required not to flush the medication down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rinisona found in:

A-Z Index: